Apimeds Pharmaceuticals US, Inc.
APUS
$1.63
-$0.15-8.43%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.12% | -48.05% | 179.85% | 7,822.22% | 4,584.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.12% | -50.71% | 187.91% | 1,438.85% | 381.74% |
| Operating Income | -34.12% | 50.71% | -187.91% | -1,438.85% | -381.74% |
| Income Before Tax | -35.72% | 45.04% | -202.27% | -1,144.88% | -358.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.72% | 45.04% | -202.27% | -1,144.88% | -358.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.72% | 45.04% | -202.27% | -1,144.88% | -358.98% |
| EBIT | -34.12% | 50.71% | -187.91% | -1,438.85% | -381.74% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -35.73% | 55.73% | -65.75% | -505.32% | -123.21% |
| Normalized Basic EPS | -35.90% | 55.76% | -65.41% | -501.69% | -122.86% |
| EPS Diluted | -35.73% | 55.73% | -65.75% | -505.32% | -123.21% |
| Normalized Diluted EPS | -35.90% | 55.76% | -65.41% | -501.69% | -122.86% |
| Average Basic Shares Outstanding | 0.00% | 24.11% | 82.44% | 105.50% | 105.50% |
| Average Diluted Shares Outstanding | 0.00% | 24.11% | 82.44% | 105.50% | 105.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |